Followers | 80 |
Posts | 3,532 |
Boards Moderated | 0 |
Alias Born | 06/04/2012 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the $100's of millions of funds to be raised
and invaluable connections are well worth the fee
this is not a pump n dump
they a leading Medical MJ Research and Science Co
Sadly you cannot buy a Hospital Based Safety Study at WalMart
Dr. Stanley Hirsch at the 2018 Wall St Conference
http://wallstconference.com/schedule-2018/
News Today - Stay Tuned to the Conference for Updates
OWCP Presents at 11:30
http://wallstconference.com/schedule-2018/
$OWCP 2 New studies starting at least
$OWCP OWC Pharmaceutical Research Corp
* Updated * 1 Pg PDF Corp Profile
see [enclosed] PDF and shareable link ...
https://drive.google.com/file/d/0B3CPcGOCWnIPZzJlYzZGWkI3eWR4X1hhRk51S0tFSFdiQ0hF/view?usp=drivesdk
Hearing CNBC and Fox Business News will be reporting at tomorrow's Wall Street conference and many financial press writers
700 registered ...
$OWCP NEWS * Dr. Oron Yacoby Zeevi Joins OWC Pharmaceutical Research Corp - OWCP
News Link 8K
https://backend.otcmarkets.com/otcapi/company/sec-filings/12562836/content/html
Profile Article
https://jewishwebsite.com/featured/meet-the-top-10-most-influential-israelis-in-international-business-science-and-culture-in-2017/23335/
The Scientist: Dr. Oron Yacoby-Zeevi
Neuroderm Chief Scientist Officer Dr. Oron Yacoby-Zeevi may seem rather unassuming when compared to some of the other game-changers on this list, but there’s a very good reason she joins the other nine candidates.
Israel’s Neuroderm, a clinical-stage pharmaceutical firm developing next-generation treatments for disorders of the central nervous system, was sold to Mitsubishi Tanabe Pharma for $1.1 billion in what is said to be Israel’s largest Pharma exit earlier this year. Yacoby-Zeevi, according to a report in Globes, had a hand in that exit, at least in part, because she is responsible for the company’s technological solution.
NeuroDerm has developed a liquid version of a drug already in existence to treat Parkinson’s Disease. This groundbreaking achievement will certainly improve the lives of patients around the world who suffer from the disease, while also generating profits for the company.
@IsraelCannabis @CNBC @CNBCI @CNN @CNNI @BW @WSJ @FT @nytimes #Marijuana #Marijuanastocks #MedicalMarijuana #MecicalCannabis @CannabisBizNews
Big week ahead
Cannabis Insider w Jeff Friedland
https://mailchi.mp/43129aab489a/debra-borchardt-699905
Intiva Biopharma New Updated Corporate Profile -
Shareable Link
https://tinyurl.com/ycmwochw
#MedicalMarijuana #MedicalCannabis #Marijuana #Marijuanastocks #JeffFriedland
sadly yes TOTAL F'ing Disaster Worse Case Scenario for those that hold
JBZY 1:100 RS
https://wyobiz.wy.gov/business/FilingDetails.aspx?eFNum=217161243108068011203050228075228024036162237117
Thats it in a nutshell we are done
Here is what everyone is missing.
The common shares will be cut back 100 for 1. That means that the current
846,941,800 shares will become 8,469,418 shares. Every common shareholder will have their shares cut by 99%.
However, the Preferred shares held by management are STILL convertible to 1.25 Billion commons. The filing specifically stated that the R/S will NOT impact the Prefs.
What does this mean??? Instead of having around 2Billion shares fully diluted, there will be 1.25 Billion post split. Thus the SP will at MOST double post split, and everyone holding commons will lose 99%...
Furthermore, there is a strong likelihood they will do some sort of financing to issue the remaining 750MM shares - creating even more dilution for those who have been diluted 99%.
Everyone is expecting the SP to correct to 100x its value post consolidation, but they won't even double...effectively, they have wiped us out. Which is what EVERYONE does to a shell.
Sadly, This will be trips shortly.
Proof of 1:100 RS $JBZY They Screwed us as best they could
should be illegal
https://wyobiz.wy.gov/business/FilingDetails.aspx?eFNum=217161243108068011203050228075228024036162237117
we are left with 1% of what we had with more dilution to come to our remaining 1%
Proof of 1:100 RS $JBZY
https://wyobiz.wy.gov/business/FilingDetails.aspx?eFNum=217161243108068011203050228075228024036162237117
we are left with 1% of what we had with more dilution to come to our remaining 1%
They Screwed us as best they could
should be illegal
$OWCP last year I recall news on Monday Tuesday and Wednesday of the Conference which was Wed March 1st 2017
http://wallstconference.com/schedule-2018/
Dr. Stanley Hirsch to Present 2018 on this coming Wednesday
China screwed the USA shareholders as best they could
1:100 is beyond gross
makes complete sense why no PR why no IR Why RO Stopped talking to anyone and no ticker updates on any website or news
after lawsuit was settled
cause the screw job was coming
now will issue more common shares post RS to dilute further
Shareholders now get 1/100 of what they had
China Preferred Shareholders get 100% of what they had
new investors post split will get 100%
shareholders now get 1%
MY ADVICE___DO NOT SELL---BUY!!!!! Great Post
MY ADVICE___DO NOT SELL---BUY!!!!!
I have been thru these and the world is not ending... This R/S is not being done for frivolous reasons---my opinion is it is for correcting the imbalance in the SS with the O/S and convertible preferred shares exceeding the A/S---and setting the Company up for uplisting---
We are anticipating very strong financials and this pps could be anywhere from .025 to .15 before the R/S is approved by FINRA and then executed---the timing is not up to the company , but FINRA---it might take them a week or a month---
By August of this year we will have seen the 10K and the first and second 10Qs---We will be listed on the NASDAQ or the NYSE by the EOY---
Great Post - Excellent Point
$KPAY 2018 Wall St Conference Schedule Posted
http://wallstconference.com/schedule-2018/
#mobilepayments #Indonesia #MobilePay #Bitcoin #ICO #KCOIN
$OWCP 2018 Wall St Conference Schedule Posted
http://wallstconference.com/schedule-2018/
#MedicalMarijuana #MedicalCannabis #Marijuana
1 week tomorrow $OWCP $OWCP - OWC Pharmaceutical Research Corporation to Present at the 2018 Wall St Conference https://t.co/lxnuJWGitl OWCP#MedicalMarijuana #MedicalCannabis #Marijuana @CannabisBizNews @CanadaPotstocks @cannabisinv #OWCP pic.twitter.com/WFBmq8flCr
Hearing there are 700 registered !!
Looking forward to seeing OWC's Dr. Stanley Hirsch Present
800 m S/O is not accounting for all the Preferred Shares
But even if we are worth $5 is a life changer for many
go $JBZY
http://roboticassistancedevices.com/blog-post/driven-passion-ai-moving-beyond-robotics/
First, it means we’ve got a new logo and an updated mission statement that better reflects RAD’s purpose and goals.
Robotic Assistance Devices’ mission is to deliver artificial intelligence-based solutions that empower organizations to solve complex challenges while delivering immediate return on investment.
Lots happening. . .https://t.co/fsmT9Y6kIg
— Steve Reinharz (@SteveReinharz) February 8, 2018
U.S. Senate Agrees on 2-Year Budget Deal, Includes Protections for Medical Marijuana and Hemp - TheJointBlog
https://thejointblog.com/u-s-senate-agrees-2-year-budget-deal-includes-protections-medical-marijuana-hemp/
U.S. Senate Agrees on 2-Year Budget Deal, Includes Protections for Medical Marijuana and Hemp - TheJointBlog
https://thejointblog.com/u-s-senate-agrees-2-year-budget-deal-includes-protections-medical-marijuana-hemp/
$KPAY NEWS
Does 1100% Revenue Growth & Crypto Currency Venture Make KPAY The Blockchain Stock to Own in 2018?
https://finance.yahoo.com/news/does-1100-revenue-growth-crypto-123000506.html
KPAY #MobilePayments #Indonesia
$NTVA @IntivaBiopharma Sr. Management Taking meetings in Toronto, Canada $OWCP @Jeff_Friedland
https://twitter.com/IntivaBiopharma/status/961317080535531522
$NTVA @IntivaBiopharma Sr. Management Taking meetings in Toronto, Canada
https://twitter.com/IntivaBiopharma/status/961317080535531522
Intiva BioPharma Comments on Attorney General Jeff Sessions’ Actions on January 4th that Affect State-Licensed Cannabis Businesses
Intiva BioPharma indicated that Sessions’ actions in no way affect its drug development activities, nor its current or contemplated business plans
Denver, Colorado: February 5, 2018 - Intiva BioPharma Inc., OTC: NTVA (“Intiva” or the “Company”), today commented on the January 4, 2018 announcement by U.S. Attorney General Jeff Sessions and the Department of Justice related to state-licensed cannabis companies in the United States.
Intiva is a U.S. based biopharmaceutical company engaged in the development of cannabinoid-based drugs under U.S. Food and Drug Administration (FDA) protocols. The Company indicated that Sessions’ actions in no way affect its drug development activities, nor its current or contemplated business plans.
In commenting on the impact of Sessions’ actions, Jeffrey Friedland, Intiva’s CEO stated, “Despite Sessions’ actions, companies involved in the development of cannabinoid-based drugs under FDA protocols remain a “safe harbor” for U.S. investors. Sessions’ actions in no way adversely affect Intiva, our drug development activities, nor our current or contemplated future business plans.”
Mr. Friedland also stated, “Prior to Sessions’ actions, our drug development activities were fully in compliance with U.S. federal law, including all provisions of the Controlled Substance Act, and now, after Sessions’ January 4th announcement, Intiva’s activities continue to be in full compliance with federal law.”
Sessions’ actions terminated the executive actions of the Obama Administration that allowed state-licensed cannabis businesses to operate under state laws, despite the illegality of cannabis federally, due to its classification as a Schedule 1 substance under the Controlled Substances Act.
Today, 29 states plus Puerto Rico and Washington DC have legalized some form of medical cannabis, and nine states have legalized, or are in the process of legalizing, adult-use or recreational cannabis. The latest national polls indicate that over 60 percent of the American public believes that cannabis should be legalized.
Despite the illegality of marijuana at the federal level, the executive actions of the Obama administration including, most importantly, the Cole Memorandum, provided a “safe-harbor” that allowed state-licensed cannabis businesses to exist, without threat of federal actions by U.S. Attorneys. The Obama Administration’s executive actions also provided a safe harbor for investors, landlords, and providers of goods and services to state-licensed cannabis businesses.
In conclusion, Intiva BioPharma and other companies who are developing cannabinoid-based drugs under U.S. Food and Drug Administration (FDA) protocols are not impacted by Sessions’ actions. In addition to Intiva BioPharma, these companies include GW Pharmaceuticals (NASDAQ: GWPH) and Insys Therapeutics (NASDAQ: INSY).
About Intiva BioPharma Inc.
Intiva BioPharma Inc. is a biopharmaceutical company with three integrated business directions:
1. Developing, licensing and commercializing cannabinoid-based medications for specific medical conditions and disorders. Our drug development activities are undertaken in accordance with Food and Drug Administration (FDA) or comparable development pathways in other countries. Our intent is that any medications we develop will be physician-prescription based.
2. The development or licensing of proprietary delivery systems for cannabinoid-based medications.
3. Investments in companies, and the acquisition of technologies, or medications, focused on cannabinoid-based research, through Special Purpose Investment Vehicles controlled by Intiva Biopharma.
Intiva Disclosure Notice:
This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein or which are otherwise made by or on behalf of the Company that are not statements of historical facts may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "to," "plan," "expect," "believe," "anticipate," "intend," "could," "should," "would," "estimate," or "continue," or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements. Readers are cautioned that all forward-looking statements involve risk and uncertainties which may cause results to differ materially from those set forth in the statements. Such risks and uncertainties include, but are not limited to the following: the success of research and development activities and the speed with which regulatory authorizations and product launches may be achieved; government regulation generally; competitive developments; the ability to successfully market products domestically and internationally; difficulties or delays in manufacturing or issues relating to manufacturing capacity; commercial obstacles to the successful introduction of brand products generally; legal defense costs, insurance expenses, settlement costs, and the risk of an adverse decision or settlement relating to product liability, patent protection, governmental investigations, and other legal proceedings; the Company's ability to acquire and protect patents and other intellectual property both domestically and internationally; the absence of certainty regarding the receipt of required regulatory approval or the timing or terms of such approvals; any changes in business, political and economic conditions; business interruption due to hurricanes or other events outside of the Company's control.
Readers are cautioned not to place reliance on these forward-looking statements, which are valid only as of the date they were made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of unanticipated events or otherwise, except as expressly required by law.
Contact:
Mark Lubchenco
Director of Shareholder and Investor Relations
Intiva BioPharma Inc.
Tel. 1-800-497-2915
Email: mlubchenco@intivabiopharma.com
Website: www.IntivaBioPharma.com
$KPAY Updated 2017 Financials
https://finance.yahoo.com/news/kinerjapay-corp-full-2017-financial-130000006.html
#MobilePay #mobilepayments #Bitcoin #ICO #InitialCoinOffering #Indonesia